Please Wait.....
Report
Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
Market Research Report I 2024-12-26 I 125 Pages I BCC Research
Description
Report Scope
This report focuses on the global market for Alzheimer's disease (AD) diagnostics and therapeutics, offering an updated review of this rapidly emerging market. In this report, the diagnostic market covers only biomarker tests for AD. Cognitive tests and neuroimaging diagnostic methods assessing structural changes are not part of the market calculations. The diagnostics market segmentation is based on the test type and region.
The therapeutics segment covers pharmacological treatments (drugs) only. This report does not cover alternative treatment options, such as procedural interventions. Additionally, many medications are used "off-label" to manage non-cognitive symptoms, such as agitation and depression, associated with dementia due to AD. This report does not cover off-label drugs used in the treatment of Alzheimer's. The therapeutics market segmentation is based on purpose, drug class, drug type, disease stage, and region.
An analysis of clinical trials, innovations, opportunities, and the latest trends in the AD diagnostics and therapeutics market are also discussed in the report.
Report Includes
- 38 data tables and 80 additional tables
- Analyses of the trends in the global market for Alzheimer's disease (AD) therapeutics and diagnostics, with market revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecasts for 2024-2025, and projected CAGRs through 2029
- Estimates of the size of the global market and revenue growth prospects, along with a market share analysis by type, therapeutic application, drug classification, mechanism of action, disease state of indication and region
- Facts and figures pertaining to key market dynamics, technological advances, regulations, and the impact of macroeconomic factors
- Identification of diagnostic tools and equipment; scientific and technological frameworks; drug profiles, clinical groundworks; and coverage of global developments
- Information on products that are currently available for the diagnosis and treatment of Alzheimer's disease, as well as the promising new drug candidates and diagnostic imaging agents
- An analysis of patents, emerging trends and the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Profiles of leading companies, including AbbVie Inc., Biogen, Eisai Co. Ltd., Eli Lilly and Co., and F. Hoffmann-La Roche Ltd.
Executive Summary
Summary:
Alzheimer's disease (AD) is a neurodegenerative condition that progresses through a continuum, starting from preclinical stages to mild cognitive and behavioral impairments, and ultimately leading to dementia. The prevalence of AD doubles each decade after ages 65 years. Given the aging population globally, the prevalence of AD is on the rise.
The global market for biomarker tests for AD screening and diagnosis was valued at $5.4 billion in 2023 and is projected to reach $8.8 billion by the end of 2029, growing at a compound annual growth rate (CAGR) of 8.7% through the forecast period. The current landscape of AD diagnosis is advancing rapidly due to improvements in nuclear imaging technology, biomarker research, and an increased focus on early detection. Biomarkers are of enormous use in the diagnosis of AD. They are objective measures, they are reproducible, and they are independent of the clinician's judgment. Cerebral spinal fluid (CSF) examination, brain imaging using positron emission tomography (PET) scans, and blood/plasma analysis are available for biomarker-based validation of AD diagnosis.
PET imaging and CSF testing are often accurate, but several limitations are attached to these testing methods, which hampers their application as a practical tool for widespread use. PET scans are costly, and CSF is a highly invasive process requiring lumbar puncture. At the time of this publication, the FDA has not approved blood biomarker tests.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Alzheimer's Disease Overview
Alzheimer's Disease Pathophysiology
AD and Amyloid Cascade
AD and Tauopathy
AD and Neurotransmitter Systems
Diagnosis of AD
Cognitive Status Testing
Brain Imaging
Lumbar Puncture
Blood-Biomarker Tests
Genetic Testing
Pharmaceutical Treatment of AD
Chapter 3 Market Dynamics
Market Dynamics Snapshot
Market Drivers
Growing Incidence of AD
High Unmet Need
Growing Focus on Biomarkers in Diagnosis and Drug Development
Increasing Public and Private investment in Neuroscience
Growing Public Awareness and Early Diagnosis
Large Number of Drugs in Late-Stage Clinical Trials
Market Restraints
High Costs of Diagnostics and Novel Therapies
Patent Expirations of Branded Drugs and Emergence of Generics
High Failure Rate in Drug Development
Chapter 4 Emerging Technologies and Developments
Emerging Technologies/Trends
Blood Tests for AD Screening and Diagnosis
Disease Modifying Small-Molecule Drugs
Re-purposed Drugs
AI and Machine Learning
Pipeline Analysis
Overview
Therapeutic Purpose Type
Novel AD Therapeutics in Development in Phase 3
By Target Type
By Disease State
Novel PET Radiotracers in Development
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Test Type
AD Biomarker Tests Market, by Test Type
AD Therapeutics Market, by Therapeutic Purpose
AD Therapeutics Market, by Drug Class
AD Therapeutics Market, by Drug Type
AD Therapeutics Market, by Disease Stage
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World (RoW)
Chapter 6 Competitive Intelligence
AD Therapeutics
Alzheimer's Generic Drug Market
Alzheimer's Branded Drug Market
Donepezil
Rivastigmine
Galantamine
Memantine
Combination Therapy (Memantine and Donepezil)
AD Diagnostics
Overview
Product Launches/Approvals in the AD Diagnostics Market
Chapter 7 Appendix
Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ALPHA COGNITION
ALZPATH INC.
AUROBINDO PHARMA
BIOGEN
C2N DIAGNOSTICS
CORIUM LLC.
DIADEM SRL
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
H.U. GROUP HOLDINGS INC.
LABORATORY CORPORATION OF AMERICA HOLDINGS
LILLY
OTSUKA HOLDINGS CO. LTD.
QUEST DIAGNOSTICS INC.
List of Tables
Summary Table : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 1 : Brain Imaging Technologies and Application in the Alzheimer's Context
Table 2 : Common Methods for AD Detection
Table 3 : Key Clinical Biomarkers Used in the Diagnosis of AD
Table 4 : NIH Funding Estimates for Alzheimer's Disease Research, 2017-2024
Table 5 : Selected AD Biomarker-Focused Consortia
Table 6 : Recent Therapeutic Programs Ceased Due to Failure in Clinical Trials
Table 7 : Selected Blood Tests in Development for AD Screening/Diagnosis
Table 8 : Disease Modifying Small Molecules AD Drug Candidates in Phase 3 Clinical Trials
Table 9 : Disease Modifying Large Molecule AD Drug Candidates in Phase 3 Clinical Trials
Table 10 : Treatments for AD-Related Neuropsychiatric and Behavioral Symptoms in Phase 3 Clinical Trials
Table 11 : Cognitive Enhancer AD Drug Candidates in Phase 3 Clinical Trials
Table 12 : Radiopharmaceuticals for CNS Imaging in Clinical Development
Table 13 : Global Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 14 : Comparison of Biomarker Tests
Table 15 : FDA-Approved PET Radiopharmaceuticals for AD Diagnosis
Table 16 : CSF-Based IVD Tests for AD
Table 17 : Blood Tests for AD Diagnosis
Table 18 : Global Market for AD Biomarker Tests, by Test Type, Through 2029
Table 19 : FDA-Approved Drugs to Treat Cognitive Symptoms of AD
Table 20 : FDA-Approved Drugs to Treat Non-Cognitive Symptoms of AD
Table 21 : Global Market for AD Therapeutics, by Therapeutic Purpose, Through 2029
Table 22 : FDA-Approved AChEIs
Table 23 : FDA-Approved Anti-Amyloid Antibodies
Table 24 : Selected Anti-Inflammatory and Neuroprotective Agents in Phase 3 Clinical Trials
Table 25 : Global Market for AD Therapeutics, by Drug Class, Through 2029
Table 26 : Anti-Amyloid Drugs in Phase 3 Clinical Development
Table 27 : Neurotransmitter Modulars in Clinical Trials Phase 3
Table 28 : Global Market for AD Therapeutics, by Drug Type, Through 2029
Table 29 : Patent Information for AD Drugs
Table 30 : Number of Companies with Active FDA Approval to Market AD drugs in the U.S.
Table 31 : FDA-Approved AD Drugs and Their Indications
Table 32 : Global Market for AD Therapeutics, by Disease Stage, Through 2029
Table 33 : Global Market for AD Therapeutics and Diagnostics, by Region, Through 2029
Table 34 : North American Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 35 : North American Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 36 : U.S. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 37 : Canadian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 38 : Mexican Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 39 : European Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 40 : Europe Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 41 : German Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 42 : French Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 43 : U.K. Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 44 : Italian Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 45 : Rest of European Countries' Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 46 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 47 : Asia-Pacific Market for AD Therapeutics and Diagnostics, by Country, Through 2029
Table 48 : Chinese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 49 : Japanese Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 50 : Rest of Asia-Pacific Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 51 : RoW Market for AD Therapeutics and Diagnostics, by Type, Through 2029
Table 52 : Key Companies in the U.S. Alzheimer's Generic Drug Market
Table 53 : Commercially Available FDA-Approved Branded AD Drugs
Table 54 : Companies with Active FDA Approval to Market Donepezil in the U.S.
Table 55 : Companies with Active FDA Approval to Market Rivastigmine in the U.S.
Table 56 : Companies with Active FDA Approval to Market Galantamine in U.S.
Table 57 : Companies with Active FDA Approval to Market Memantine in the U.S.
Table 58 : Companies with Active FDA Approval to Market Combination Therapy (Memantine and Donepezil) in the U.S.
Table 59 : Selected Product Approvals/Launches in the AD Diagnostics Market, 2022-2024
Table 60 : Information Sources in this Report
Table 61 : Abbreviations Used in This Report
Table 62 : AbbVie Inc.: Company Snapshot
Table 63 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 64 : AbbVie Inc.: Product Portfolio
Table 65 : AbbVie Inc.: News/Key Developments, 2024
Table 66 : Alpha Cognition: Company Snapshot
Table 67 : Alpha Cognition: Financial Performance, FY 2022 and 2023
Table 68 : Alpha Cognition: Product Portfolio
Table 69 : Alpha Cognition: News/Key Developments, 2024
Table 70 : ALZpath Inc.: Company Snapshot
Table 71 : ALZpath Inc.: Product Portfolio
Table 72 : ALZpath Inc.: News/Key Developments, 2023 and 2024
Table 73 : Aurobindo Pharma: Company Snapshot
Table 74 : Aurobindo Pharma: Financial Performance, FY 2022 and 2023
Table 75 : Aurobindo Pharma: Product Portfolio
Table 76 : Aurobindo Pharma: News/Key Developments, 2023
Table 77 : Biogen: Company Snapshot
Table 78 : Biogen: Financial Performance, FY 2022 and 2023
Table 79 : Biogen: Product Portfolio
Table 80 : Biogen: News/Key Developments, 2023 and 2024
Table 81 : C?N Diagnostics: Company Snapshot
Table 82 : C?N Diagnostics: Product Portfolio
Table 83 : C?N Diagnostics: News/Key Developments, 2023 and 2024
Table 84 : Corium LLC.: Company Snapshot
Table 85 : Corium LLC.: Product Portfolio
Table 86 : Corium LLC.: News/Key Developments, 2022 and 2023
Table 87 : Diadem srl: Company Snapshot
Table 88 : Diadem srl: Product Portfolio
Table 89 : Diadem srl: News/Key Developments, 2022 and 2023
Table 90 : Eisai Co. Ltd.: Company Snapshot
Table 91 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 92 : Eisai Co. Ltd.: Product Portfolio
Table 93 : Eisai Co. Ltd.: News/Key Developments, 2022-2024
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98 : H.U. Group Holdings Inc.: Company Snapshot
Table 99 : H.U. Group Holdings Inc.: Financial Performance, FY 2022 and 2023
Table 100 : H.U. Group Holdings Inc.: Product Portfolio
Table 101 : H.U. Group Holdings Inc.: News/Key Developments, 2022-2024
Table 102 : Laboratory Corporation of America Holdings: Company Snapshot
Table 103 : Laboratory Corporation of America Holdings: Financial Performance, FY 2022 and 2023
Table 104 : Laboratory Corporation of America Holdings: Product Portfolio
Table 105 : Laboratory Corporation of America Holdings: News/Key Developments, 2022-2024
Table 106 : Lilly: Company Snapshot
Table 107 : Lilly: Financial Performance, FY 2022 and 2023
Table 108 : Lilly: Product Portfolio
Table 109 : Lilly: News/Key Developments, 2024
Table 110 : Otsuka Holdings Co. Ltd.: Company Snapshot
Table 111 : Otsuka Holdings Co. Ltd: Financial Performance, FY 2022 and 2023
Table 112 : Otsuka Holdings Co. Ltd: Product Portfolio
Table 113 : Otsuka Holdings Co. Ltd: News/Key Developments, 2023 and 2024
Table 114 : Quest Diagnostics Inc.: Company Snapshot
Table 115 : Quest Diagnostics Inc.: Financial Performance, FY 2022 and 2023
Table 116 : Quest Diagnostics Inc.: Product Portfolio
Table 117 : Quest Diagnostics Inc.: News/Key Developments, 2022-2024
List of Figures
Summary Figure : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 1 : Hypothetical Models for Progression of Alzheimer's Disease
Figure 2 : Market Dynamics of Alzheimer's Disease Therapeutics and Diagnostics
Figure 3 : Breakdown of Global Aging Population (65 or Older) with Alzheimer's-Associated Dementia, by Age Group, 2023
Figure 4 : Breakdown of Dementia Cases in Japan, by Disease Type
Figure 5 : Alzheimer's and Related Dementia Research Funding at the NIH, 2013-2023
Figure 6 : Potential Use of Blood-Based Biomarkers in Primary Care
Figure 7 : Novel Industry-Sponsored AD Therapeutic Agents in Clinical Development, by Clinical Trial Phase
Figure 8 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Type
Figure 9 : Share of Phase 3 AD Drug Development Pipeline, by Therapeutic Purpose Subtype
Figure 10 : Number of AD Clinical Trials for Most Common Targets, by Phase, as of Oct. 2024
Figure 11 : Share of Active Clinical Trials for AD, by Disease State, as of Oct. 2024
Figure 12 : Global Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 13 : Global Market Shares of AD Biomarker Tests, by Test Type, 2023
Figure 14 : Global Market Shares of AD Therapeutics, by Therapeutic Purpose, 2023
Figure 15 : Global Market Shares of AD Therapeutics, by Drug Class, 2023
Figure 16 : Global Market Shares of AD Therapeutics, by Drug Type, 2023
Figure 17 : Alzheimer's Disease (AD) Continuum
Figure 18 : Global Market Shares of AD Therapeutics, by Disease Stage, 2023
Figure 19 : Global Market for AD Therapeutics and Diagnostics, by Region, 2021-2029
Figure 20 : Global Market Shares of AD Therapeutics and Diagnostics, by Region, 2023
Figure 21 : North American Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 22 : North American Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 23 : European Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 24 : European Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 25 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 26 : Asia-Pacific Market Shares of AD Therapeutics and Diagnostics, by Country, 2023
Figure 27 : RoW Market Shares of AD Therapeutics and Diagnostics, by Type, 2023
Figure 28 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 29 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 30 : Aurobindo Pharma: Revenue Share, by Business Unit, FY 2023
Figure 31 : Aurobindo Pharma: Revenue Share, by Country/Region, FY 2023
Figure 32 : Biogen: Revenue Share, by Business Unit, FY 2023
Figure 33 : Biogen: Revenue Share, by Country/Region, FY 2023
Figure 34 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Eisai Co. Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 36 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
Figure 37 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
Figure 38 : Laboratory Corporation of America Holdings: Revenue Share, by Business Unit, FY 2023
Figure 39 : Lilly: Revenue Share, by Business Unit, FY 2023
Figure 40 : Lilly: Revenue Share, by Country/Region, FY 2023
Figure 41 : Otsuka Holdings Co. Ltd: Revenue Share, by Business Unit, FY 2023
Figure 42 : Otsuka Holdings Co. Ltd: Revenue Share, by Country/Region, FY 2023
Figure 43 : Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security